Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ · Healthcare
Zentalis Pharmaceuticals, Inc. annual/quarterly shareholder equity history from 2022 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Zentalis Pharmaceuticals, Inc. shareholder equity for the quarter ending December 31, 2025 were 216.2M, a 35.88% decrease year-over-year.
- Zentalis Pharmaceuticals, Inc. shareholder equity for 2025 were 216.2M, a 35.88% decrease from 2024.
- Zentalis Pharmaceuticals, Inc. shareholder equity for 2024 were 337.2M, a 22.89% decrease from 2023.
- Zentalis Pharmaceuticals, Inc. shareholder equity for 2023 were 437.3M, a 0.80% increase from 2022.
- Zentalis Pharmaceuticals, Inc. shareholder equity for 2022 were 433.8M.
Shareholder Equity
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| Zentalis Pharmaceuticals, Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $216 |
| 2024 | $337 |
| 2023 | $437 |
| 2022 | $434 |
| Zentalis Pharmaceuticals, Inc. Quarterly Shareholder Equity (Millions of US $) | |
|---|---|
| 2025-12-31 | $216 |
| 2024-12-31 | $337 |
| 2023-12-31 | $437 |
| 2022-12-31 | $434 |
Zentalis Pharmaceuticals, Inc. Shareholder Equity — FAQ
Zentalis Pharmaceuticals, Inc. (ZNTL) shareholder equity over the last 4 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see ZNTL's shareholder equity history?
The chart and table above show Zentalis Pharmaceuticals, Inc.'s shareholder equity by year and by quarter, including the growth rate.